Printer Friendly

THE LIPOSOME COMPANY'S ABLC AVAILABLE IN SOUTH AFRICA TO TREAT AIDS RELATED CRYPTOCOCCAL MENINGITIS

 PRINCETON, N.J., Sept. 28 /PRNewswire/ -- The Liposome Company, Inc. (NASDAQ: LIPO) has initiated named patient distribution of ABLC(TM) (amphotericin B lipid complex) in the Republic of South Africa, including two AIDS patients with cryptococcal meningitis who have received the drug so far.
 Cryptococcal meningitis is a type of fungal infection which occurs in up to 10 percent of patients with AIDS, with about 20 percent of the patients dying within 30 days of diagnosis.
 "This is the next step in The Liposome Company's plan to make ABLC available to patients suffering from life-threatening fungal infections, worldwide," said Charles A. Baker, chairman and chief executive officer of The Liposome Company. "There are a large number of AIDS patients in South Africa, and therefore cryptococcal meningitis is a serious problem. The named patient distribution program will make ABLC available to these patients and will also allow us to gather quickly important data on the drug's efficacy and safety in this terrible disease."
 In addition, the company is preparing an application for approval to market ABLC in Europe. ABLC is already available on a compassionate use basis in the U.S. and Europe for patients with life-threatening systemic fungal infections for whom currently marketed drugs are ineffective or too toxic. To date, about 250 patients have received the drug in the U.S. ABLC compassionate program. Several hundred more have been treated in controlled clinical trials in the U.S., including a trial in AIDS patients with cryptococcal meningitis. Additional large U.S. Phase III trials in several types of life-threatening systemic fungal infections are now being planned.
 ABLC, a proprietary new drug, consists of amphotericin B in a lipid complex. Conventional amphotericin B, without the lipid complex, is a broad-spectrum polyene antifungal agent which has been marketed for many years for the treatment of systemic fungal infections in patients who are immunocompromised, such as people with AIDS, cancer chemotherapy patients, and organ transplant recipients. While the old version of amphotericin B generally is considered the "gold standard" treatment against such infections as candidiasis, cryptococcal meningitis, and aspergillosis, its usefulness has been limited by its potential to cause side effects, especially kidney toxicity and anemia. By incorporating amphotericin B in a lipid complex, clinical results to date indicate that ABLC may significantly reduce the risk of toxicity while maintaining or increasing efficacy.
 A leading company dedicated exclusively to the development of liposome and lipid-based pharmaceuticals, The Liposome Company develops proprietary parenteral pharmaceuticals for the treatment, prevention, and diagnosis of life-threatening diseases. In addition to ABLC, the company has three other drugs currently in clinical trials, Maitec(TM) (formerly TLC G-65) is in Phase II trials in the U.S. and Phase III trials in Europe for the treatment of Mycobacterium avium-intracellulare (MAI), an infection that eventually strikes 30 to 50 percent of people with AIDS; TLC D-99 has completed Phase II for treatment of metastatic breast cancer; and TLC C-53 has completed Phase I trials in preparation for a Phase II study in Acute Respiratory Distress Syndrome.
 -0- 9/28/93
 /CONTACT: Brooks Boveroux, vice president - finance and CFO of The Liposome Company, Inc., 609-452-7060/
 (LIPO)


CO: The Liposome Company, Inc. ST: New Jersey IN: MTC SU: PDT

LD -- NY011 -- 6250 09/28/93 09:16 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 28, 1993
Words:546
Previous Article:EG&G ANTICIPATES WEAKER THAN EXPECTED THIRD QUARTER AND FULL YEAR EARNINGS
Next Article:ALLIED WASTE INDUSTRIES, INC. ANNOUNCES $27.3 MILLION PRIVATE PLACEMENT
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters